Primary Monosymptomatic Nocturnal Enuresis: Monotherapy vs Combination Therapy

Area of Science:

• Pediatric Urology
• Pharmacological Treatments
• Nocturnal Enuresis Management

Background:

• Primary monosymptomatic nocturnal enuresis (PMNE) affects many children, impacting quality of life.
• Current treatment options include monotherapy, but combination therapy may offer improved outcomes.

Purpose of the Study:

• To compare the clinical effectiveness of desmopressin monotherapy versus combination therapy (desmopressin plus tolterodine) for pediatric PMNE.

Main Methods:

• A retrospective review of 176 children with PMNE treated with either desmopressin melt (monotherapy) or desmopressin melt plus tolterodine (combination therapy).
• Treatment response was assessed at 1-3 months, and relapse rates were evaluated 6 months post-treatment.

Main Results:

• Combination therapy demonstrated significantly higher complete and partial response rates (93.47% at 3 months) compared to monotherapy (73.9% at 3 months).
• The relapse rate for PMNE was lower in the combination therapy group (9.09%) versus the monotherapy group (16.39%) at 6 months post-treatment.

Conclusions:

• Combination therapy with desmopressin melt and tolterodine is a more effective first-line treatment for pediatric PMNE than desmopressin monotherapy.
• This combination therapy offers sustained efficacy and reduced relapse rates in managing childhood enuresis.